Author

Eric Padron

Moffitt Cancer CenterORCID 0000-0002-4707-7916Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Eric Padron1 paper

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Genetics· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 3 Organism:human· 3 Approach:statistical model· 3 Research Focus:cell type annotation· 2 Assay:whole-exome sequencing· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:clustering· 1

Frequent Co-Authors

Nancy GillisiD· 2 shared Ahmet ZehiriD· 1 shared Aijazuddin SyediD· 1 shared Akshar Patel· 1 shared Andrew L. YoungiD· 1 shared Antonin Berthon· 1 shared Barbara G. SpitzeriD· 1 shared Benjamin L. EbertiD· 1 shared

Activity by Year

2019-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersGenetics

Nancy GillisORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Single-cell RNA editing defines clinically relevant cellular states in chronic myelomonocytic leukemia

Nisansala Wickramasinghe, Doan Bui, Surendra Neupane, Meghan C. Ferrall‐Fairbanks, Michael W. Deininger, Eric Padron, Tongjun Gu

This study identifies RNA editing-defined cellular states in CMML that correlate with clinical outcomes and therapeutic response.

Haematologica · Sep 3, 2026Peer-reviewedCancer Biology

MYST acetyltransferases are a targetable therapeutic vulnerability in SETBP1-mutant leukemia

Hanqian L. Carlson, Thai T Nguyen, Samantha Tauchmann, Sarah A. Carratt, Traci L. Kruer, Nana Adjoa Ben-Crentsil, Maria E. Balasis, Hyeyoon Kim, Chia‐Feng Tsai, Tao Liu, Shawn B. Shrestha, Jared Michael Fischer, Eric Padron, Theodore P. Braun, Julia E. Maxson

This study identifies MYST acetyltransferases as therapeutic targets in SETBP1-mutant leukemia, showing that MYST inhibitors reduce target gene expression and improve survival in mouse models.

bioRxiv · Jan 8, 2026 · PreprintCancer Biology

Clonal hematopoiesis is associated with increased toxicity in large B-cell lymphoma patients treated with chimeric antigen receptor T cell therapy

Neeraj Y. Saini, David M. Swoboda, Uri Greenbaum, Jungsheng Ma, Romil D. Patel, Kartik Devashish, Kaberi Das, Mark R. Tanner, Paolo Strati, Ranjit K. Nair, Luis Fayad, Sairah Ahmed, Hun Ju Lee, Swaminathan P. Iyer, Raphael Eric Steiner, , Koichi Takahashi

This study finds that clonal hematopoiesis mutations, particularly in DNMT3A, TET2, and ASXL1, are linked to increased toxicity in patients undergoing anti-CD19 CAR T-cell therapy for large B-cell lymphoma.

bioRxiv · Sep 28, 2021 · PreprintGenetics

Oncologic Therapy Shapes the Fitness Landscape of ClonalHematopoiesis

Kelly L. Bolton, Ryan N. Ptashkin, Teng Gao, Lior Zvi Braunstein, Sean M. Devlin, Daniel John Kelly, Minal A. Patel, Antonin Berthon, Aijazuddin Syed, Mariko Yabe, Catherine Callaghan Coombs, Nicole M. Caltabellotta, Mike Walsh, Kenneth Offit, Zsofia Kinga Stadler, , Elli Papaemmanuil

The paper shows oncologic therapy increases clonal hematopoiesis with DDR mutations, which predicts risk of therapy-related myeloid neoplasms.

bioRxiv · Nov 20, 2019 · PreprintGenetics